Nano-Pharmacokinetics and Theranostics
-10%
portes grátis
Nano-Pharmacokinetics and Theranostics
Advancing Cancer Therapy
Kumar, Nitesh; Thorat, Nanasaheb D.
Elsevier Science & Technology
07/2021
324
Mole
Inglês
9780323850506
15 a 20 dias
680
Descrição não disponível.
Section I: Nano-Pharmacokinetics Current state of the art 1. Introduction 2. Nano-Pharmacokinetics (NPK): Current state of the art 3. Engineered Nanomaterials and Pharmacokinetics
Section II: Nano-Pharmacokinetics Clinical development 4. Nano-Pharmacokinetics: Bio distribution and toxicology 5. Biological systems and Nano-Pharmacokinetics 6. Nano-Pharmacokinetics Assessment
Section III: Nano-Pharmacokinetics and cancer 7. Clinical significance of nanomaterials in cancer treatment 8. Nano-Pharmacokinetics and Theranostics: Co relation 9. Nano-Pharmacokinetics key role in cancer theranostics 10. Nano-Pharmacokinetics key role in in vivo imaging Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship 11. Nano-Pharmacokinetics Preclinical to Clinical Translation 12. Current pre-clinical stage of Nano-Pharmacokinetics 13. Advances in Clinical translation of Nano-Pharmacokinetics 14. Future Outlook and Conclusion
Section II: Nano-Pharmacokinetics Clinical development 4. Nano-Pharmacokinetics: Bio distribution and toxicology 5. Biological systems and Nano-Pharmacokinetics 6. Nano-Pharmacokinetics Assessment
Section III: Nano-Pharmacokinetics and cancer 7. Clinical significance of nanomaterials in cancer treatment 8. Nano-Pharmacokinetics and Theranostics: Co relation 9. Nano-Pharmacokinetics key role in cancer theranostics 10. Nano-Pharmacokinetics key role in in vivo imaging Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship 11. Nano-Pharmacokinetics Preclinical to Clinical Translation 12. Current pre-clinical stage of Nano-Pharmacokinetics 13. Advances in Clinical translation of Nano-Pharmacokinetics 14. Future Outlook and Conclusion
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?Bioavailability; Bioavailability and recurrent doses; Biodistribution; Biological systems; Cancer; Cancer chemotherapy; Cancer theranostics; Chemical composition tumor; Clinical trials; Deposition; Diagnosis; Diagnostics; Drug delivery; Drug release; Efficacy; Engineered nanomaterials; Engineered nanomaterials (ENMs); Environmental safety; Exit clearance; Extracellular matrix; Extravasation and retention; Health effects; Human exposure; Imaging; In vivo; Intracellular environment; Manufacturing; Microenvironment; Modes of administration; Nano drug delivery system; Nano-pharmacodynamic; Nano-pharmacokinetics; Nanoconjugates; Nanoformulation; Nanomaterials; Nanomedicine; Nanomedicines; Nanoparticles; Nanothechnology; Nanotheranostics; Nanotoxicity; Opsonins; Optimization; Particle shapes; Particle size; Personalized medicine; Phagocytosis; Pharmacokinetics; Pharmacokinetics and pharmacodynamics; Physicochemical properties; Regulation; Regulations; Reticuloendothelial system (RES); Shape; Sheath particles; Size; Targeted delivery; Targeting; Targeting ligands; Theranostics; Therapeutics; Toxicity; Toxicology; X
Section I: Nano-Pharmacokinetics Current state of the art 1. Introduction 2. Nano-Pharmacokinetics (NPK): Current state of the art 3. Engineered Nanomaterials and Pharmacokinetics
Section II: Nano-Pharmacokinetics Clinical development 4. Nano-Pharmacokinetics: Bio distribution and toxicology 5. Biological systems and Nano-Pharmacokinetics 6. Nano-Pharmacokinetics Assessment
Section III: Nano-Pharmacokinetics and cancer 7. Clinical significance of nanomaterials in cancer treatment 8. Nano-Pharmacokinetics and Theranostics: Co relation 9. Nano-Pharmacokinetics key role in cancer theranostics 10. Nano-Pharmacokinetics key role in in vivo imaging Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship 11. Nano-Pharmacokinetics Preclinical to Clinical Translation 12. Current pre-clinical stage of Nano-Pharmacokinetics 13. Advances in Clinical translation of Nano-Pharmacokinetics 14. Future Outlook and Conclusion
Section II: Nano-Pharmacokinetics Clinical development 4. Nano-Pharmacokinetics: Bio distribution and toxicology 5. Biological systems and Nano-Pharmacokinetics 6. Nano-Pharmacokinetics Assessment
Section III: Nano-Pharmacokinetics and cancer 7. Clinical significance of nanomaterials in cancer treatment 8. Nano-Pharmacokinetics and Theranostics: Co relation 9. Nano-Pharmacokinetics key role in cancer theranostics 10. Nano-Pharmacokinetics key role in in vivo imaging Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship 11. Nano-Pharmacokinetics Preclinical to Clinical Translation 12. Current pre-clinical stage of Nano-Pharmacokinetics 13. Advances in Clinical translation of Nano-Pharmacokinetics 14. Future Outlook and Conclusion
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?Bioavailability; Bioavailability and recurrent doses; Biodistribution; Biological systems; Cancer; Cancer chemotherapy; Cancer theranostics; Chemical composition tumor; Clinical trials; Deposition; Diagnosis; Diagnostics; Drug delivery; Drug release; Efficacy; Engineered nanomaterials; Engineered nanomaterials (ENMs); Environmental safety; Exit clearance; Extracellular matrix; Extravasation and retention; Health effects; Human exposure; Imaging; In vivo; Intracellular environment; Manufacturing; Microenvironment; Modes of administration; Nano drug delivery system; Nano-pharmacodynamic; Nano-pharmacokinetics; Nanoconjugates; Nanoformulation; Nanomaterials; Nanomedicine; Nanomedicines; Nanoparticles; Nanothechnology; Nanotheranostics; Nanotoxicity; Opsonins; Optimization; Particle shapes; Particle size; Personalized medicine; Phagocytosis; Pharmacokinetics; Pharmacokinetics and pharmacodynamics; Physicochemical properties; Regulation; Regulations; Reticuloendothelial system (RES); Shape; Sheath particles; Size; Targeted delivery; Targeting; Targeting ligands; Theranostics; Therapeutics; Toxicity; Toxicology; X
